Lenalidomide and Obinutuzumab for Previously Untreated CLL

NCT02371590 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Study Not Activated Due to Contract Issues

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Lenalidomide
DRUG: Obinutuzumab

Sponsor

University of California, San Diego

Collaborators

[object Object]
[object Object]